Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1693591rdf:typepubmed:Citationlld:pubmed
pubmed-article:1693591lifeskim:mentionsumls-concept:C1335513lld:lifeskim
pubmed-article:1693591lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:1693591lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1693591pubmed:issue6lld:pubmed
pubmed-article:1693591pubmed:dateCreated1990-7-16lld:pubmed
pubmed-article:1693591pubmed:abstractTextTwelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lymph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.lld:pubmed
pubmed-article:1693591pubmed:languageenglld:pubmed
pubmed-article:1693591pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:citationSubsetIMlld:pubmed
pubmed-article:1693591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1693591pubmed:statusMEDLINElld:pubmed
pubmed-article:1693591pubmed:monthJunlld:pubmed
pubmed-article:1693591pubmed:issn0046-8177lld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:AyalaA GAGlld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:LoJ SJSlld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:GrignonD JDJlld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:OrdonezN GNGlld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:FernandezP...lld:pubmed
pubmed-article:1693591pubmed:authorpubmed-author:WishnowK IKIlld:pubmed
pubmed-article:1693591pubmed:issnTypePrintlld:pubmed
pubmed-article:1693591pubmed:volume21lld:pubmed
pubmed-article:1693591pubmed:ownerNLMlld:pubmed
pubmed-article:1693591pubmed:authorsCompleteYlld:pubmed
pubmed-article:1693591pubmed:pagination593-600lld:pubmed
pubmed-article:1693591pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:meshHeadingpubmed-meshheading:1693591-...lld:pubmed
pubmed-article:1693591pubmed:year1990lld:pubmed
pubmed-article:1693591pubmed:articleTitleMucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies.lld:pubmed
pubmed-article:1693591pubmed:affiliationDepartment of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.lld:pubmed
pubmed-article:1693591pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1693591pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed